Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
Authors
Keywords
Immunotherapy, Cancer, Immune checkpoint inhibitors, Tuberculosis
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-04
DOI
10.1186/s40425-019-0717-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway
- (2019) Shuhui Cao et al. Cell Death & Disease
- Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future
- (2019) Martin Rao et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis
- (2019) Martin Rao et al. CURRENT OPINION IN PULMONARY MEDICINE
- Adverse events 2.0—Let us get SERIOs
- (2019) Lucie Heinzerling et al. EUROPEAN JOURNAL OF CANCER
- Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer
- (2018) Kristian Hastoft Jensen et al. ACTA ONCOLOGICA
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
- (2018) H. Picchi et al. CLINICAL MICROBIOLOGY AND INFECTION
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
- (2018) J.W. Baddley et al. CLINICAL MICROBIOLOGY AND INFECTION
- Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
- (2018) Maarten Versteven et al. Frontiers in Immunology
- Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition
- (2018) Paul T Elkington et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti- Mycobacterium tuberculosis agents
- (2018) So Takata et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
- (2018) Dick Menzies et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines
- (2018) Tasnim Hasan et al. BMJ Open
- Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies
- (2018) Jay A Fishman et al. CLINICAL INFECTIOUS DISEASES
- Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
- (2018) Graeme Meintjes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment
- (2018) C -C Tsai et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report
- (2018) Wan He et al. OncoTargets and Therapy
- Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis
- (2017) Claudia C. Dobler et al. EUROPEAN RESPIRATORY JOURNAL
- Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti–PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma
- (2017) Yi-Chun Chu et al. Journal of Thoracic Oncology
- Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model
- (2017) Abriana Tasillo et al. JAMA Internal Medicine
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma
- (2016) Joycelyn J. X. Lee et al. ACTA ONCOLOGICA
- Diagnosis of Latent Tuberculosis Infection: Too Soon to Pull the Plug on the Tuberculin Skin Test
- (2016) Lauren F. Collins et al. ANNALS OF INTERNAL MEDICINE
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
- (2016) Maria Del Castillo et al. CLINICAL INFECTIOUS DISEASES
- Screening for Latent Tuberculosis Infection in Adults
- (2016) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
- (2016) Kohei Fujita et al. Journal of Thoracic Oncology
- Cancer-specific incidence rates of tuberculosis
- (2016) Gi Hyeon Seo et al. MEDICINE
- The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis
- (2016) Lei Shen et al. TUBERCULOSIS
- CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease
- (2016) Shunsuke Sakai et al. PLoS Pathogens
- PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis
- (2016) Lei Shen et al. Scientific Reports
- Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries
- (2015) Haileyesus Getahun et al. EUROPEAN RESPIRATORY JOURNAL
- Immunosuppression Associated With Novel Chemotherapy Agents and Monoclonal Antibodies
- (2014) Vicki A. Morrison CLINICAL INFECTIOUS DISEASES
- Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis
- (2014) Qiaoling Ruan et al. CLINICAL RHEUMATOLOGY
- Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis
- (2014) J. O. Jurado et al. JOURNAL OF IMMUNOLOGY
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Epidemiology of active tuberculosis in lung cancer patients: a systematic review
- (2013) Antonis Christopoulos et al. Clinical Respiratory Journal
- Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
- (2012) Elizabeth C. Hsia et al. ARTHRITIS AND RHEUMATISM
- Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells
- (2012) Jamma Trinath et al. JOURNAL OF INFECTIOUS DISEASES
- PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
- (2012) Sonia Norris et al. VIRAL IMMUNOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection
- (2011) Sultan Tousif et al. PLoS One
- Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study
- (2011) Claudia C. Dobler et al. PLoS One
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Head and neck cancer
- (2010) David M. Cognetti et al. CANCER
- HIV Infection–Associated Tuberculosis: The Epidemiology and the Response
- (2010) Haileyesus Getahun et al. CLINICAL INFECTIOUS DISEASES
- CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition
- (2010) D. L. Barber et al. JOURNAL OF IMMUNOLOGY
- Role Played by the Programmed Death‐1–Programmed Death Ligand Pathway during Innate Immunity againstMycobacterium tuberculosis
- (2010) Ivana B. Alvarez et al. JOURNAL OF INFECTIOUS DISEASES
- Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
- (2010) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
- (2009) F. Tubach et al. ARTHRITIS AND RHEUMATISM
- Tuberculosis in Solid‐Organ Transplant Recipients: Consensus Statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology
- (2009) José María Aguado et al. CLINICAL INFECTIOUS DISEASES
- Tuberculosis and diabetes mellitus: convergence of two epidemics
- (2009) Kelly E Dooley et al. LANCET INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More